O-linked β-N-acetylglucosamine (O-GlcNAc) is an essential regulatory post-translational modification of thousands of nuclear, cytoplasmic and mitochondrial proteins. O-GlcNAc is dynamically added and removed from proteins by the O-GlcNAc transferase and the O-GlcNAcase (OGA), respectively. Dysregulation of O-GlcNAc-cycling is implicated in the etiology of numerous diseases including tumorigenesis, metabolic dysfunction and neurodegeneration. To facilitate studies focused on the role of O-GlcNAc and OGA in disease, we sought to identify commercially available antibodies that enable the enrichment of full-length OGA (fOGA) from lysates of mouse and human origin. Here, we report that antibodies from Abcam and Bethyl Laboratories can be used to immunoprecipitate OGA to near-saturation from human and mouse cell lysates. However, western blotting analysis indicates that both antibodies, as well as three noncommercially available antibodies (345, 346, 352), detect fOGA and numerous cross-reacting proteins. These nonspecific signals migrate similarly to fOGA and are detected robustly, suggesting that the use of appropriate controls is essential to avoid the misidentification of OGA.
Introduction
O-linked β-N-acetylglucosamine (O-GlcNAc) is a regulatory posttranslational modification of nuclear, cytoplasmic and mitochondrial proteins that plays key roles in cellular physiology and disease progression such as metabolic dysfunction, tumorigenesis and neurodegeneration (Hart et al. 2011; Groves et al. 2013; Bond and Hanover 2015; Martinez et al. 2017) . Underpinning these observations are thousands of O-GlcNAc-modified proteins that regulate a broad range of cellular processes including epigenetics, transcription, translation, the cell cycle and survival signaling (Hart et al. 2011; Groves et al. 2013; Bond and Hanover 2015; Martinez et al. 2017) . The dynamic cycling of O-GlcNAc on proteins is regulated by the concerted actions of enzymes encoded by just two genes: the O-GlcNAc transferase (OGT) (Haltiwanger et al. 1992; Kreppel et al. 1997; Lubas et al. 1997 ) and the O-GlcNAcase (OGA) (Dong and Hart 1994; Gao et al. 2001; Wells et al. 2002) , which add and remove O-GlcNAc, respectively. Highlighting their importance, OGT and OGA are essential for the viability of mice (Shafi et al. 2000; O'Donnell et al. 2004; Yang et al. 2012; Keembiyehetty et al. 2015) .
OGA is a neutral pH N-acetylglucosaminidase (Comtesse et al. 2001; Gao et al. 2001; Wells et al. 2002) encoded by the meningioma expressed antigen 5 (mgea5) gene. To date, five splice variants of OGA have been reported (Heckel et al. 1998; Comtesse et al. 2001; Gao et al. 2001; Schultz and Pils 2002; Wells et al. 2002; Toleman et al. 2004; Li et al. 2010; Keembiyehetty et al. 2011) . Full-length OGA (fOGA; 916 amino acids; Figure 1A ), the most abundant isoform, contains an N-terminal 350 amino acid catalytic domain and a C-terminal histone acetyltransferase (HAT)-like domain that are separated by a linker region (Comtesse et al. 2001; Schultz and Pils 2002; Rao et al. 2013) . The 677 amino acid variant of OGA contains the same N-terminus as fOGA, but lacks the HAT-like domain and has an alternative C-terminal sequence (Comtesse et al. 2001; Schultz and Pils 2002; Kim et al. 2006; Li et al. 2010; Keembiyehetty et al. 2011) . Additional isoforms include short OGA (Li et al. 2010) , which contains only the catalytic domain, and two splice variants of rat origin that lack amino acids 250-345/398 (Toleman et al. 2004) .
Since the discovery of O-GlcNAc in 1984, the development of tools to probe O-GlcNAc-signaling has been critical for understanding its role in regulating cellular physiology. While a cohort of antibodies has been developed for detecting and enriching O-GlcNAc and OGT, specific antibodies for probing OGA in a broad range of sample types/sources have lagged behind. The majority of OGA antibodies generated to date were raised against sequences from human OGA. Despite~97% sequence identity between the human and mouse homologs of OGA, existing antibodies preferentially recognize human OGA and do not efficiently enrich mouse OGA. Thus, the goal of this study was to identify commercially available antibodies that enrich OGA to saturation from both human and mouse sources. These studies focused on antibodies from Abcam and Bethyl Laboratories, herein referred to as OGA-A and OGA-B, respectively. OGA-A was raised against a synthetic N-terminal peptide derived from human OGA (proprietary; Figure 1A ), and is reported to react with both human and mouse OGA for western blotting and immunoprecipitation applications. OGA-B, which was raised against amino acids 500-550 ( Figure 1A) , is reported to react with only human OGA and is recommended for immunoprecipitation and western blot (WB) detection of enriched OGA. This study also utilized noncommercially available antibodies (OGA-345, OGA-346, OGA-352) (Butkinaree et al. 2008) , and the antigens used to generate these antibodies are outlined in Figure 1A . Our studies demonstrate that all of the antibodies tested recognize fOGA by WB and that both commercially available antibodies enrich fOGA from human and mouse lysates. However, the presence of cross-reacting bands with a similar migration pattern to fOGA, especially in mouse cell lysates, suggests that careful antibody selection and data analysis are essential.
Results and discussion

Detection of OGA by western blotting
To verify the specificity of OGA antibodies for western blotting, we utilized lysates (15 μg) of human and mouse origin that included: . OGA-345 was used at high (0.33 μg/mL) and low (0.033 μg/mL) concentrations. Protein load was assessed by western blotting for HSC70 and by Sypro Ruby total protein staining. The star indicates fOGA. This figure is available in black and white in print and in color at Glycobiology online.
U2OS human osteosarcoma cells, HEPG2 human hepatocellular carcinoma cells, mouse liver tissue, OGA wild type (WT) and null mouse embryonic fibroblasts (MEFs) (Keembiyehetty et al. 2015; OlivierVan Stichelen et al. 2017) , and OGT WT and null MEFs (Kazemi et al. 2010) . Notably, OGA expression is tightly regulated by O-GlcNAc levels (Slawson et al. 2005; Kazemi et al. 2010; Ghosh et al. 2014; Zhang et al. 2014) , and we have previously demonstrated that OGA protein levels are significantly reduced in OGT null cells (Kazemi et al. 2010 ). As such, lysates from OGT null MEFs are a negative control for the detection of both OGT and OGA. OGA was detected by WB using the following antibodies: OGA-A, OGA-B, OGA-352, OGA-345 and OGA-346 ( Figure 1B ). WBs were also performed using antibodies raised against O-GlcNAc, OGT and HSC70 (loading control), and membranes were stained with Sypro Ruby as an additional loading control ( Figure 1B) .
As expected, we observe a band at~130 kDa using each OGA antibody that is not present in the OGT and OGA null MEFs ( Figure 1B, star) , suggesting that this band represents fOGA. OGA-A also detects strong signals at~150 kDa and~75 kDa in WT MEF lysates that are not reduced in the OGT and OGA nulls ( Figure 1B) . These data suggest that the only signal specific to OGA is that at 130 kDa. OGA-B recognizes numerous bands, only one of which is significantly decreased by deletion of OGA and which migrates at 130 kDa (fOGA). In U2OS cells, but not HEPG2 cells, OGA-B also detects a doublet at~130 kDa ( Figure 1B) . The presence of these additional bands likely underpins the application note from Bethyl Laboratories stating that this antibody does not perform satisfactorily for WBs in crude lysates. Each of the noncommercial OGA antibodies (352, 345, 346) recognizes fOGA in the human and mouse samples tested, although cross-reactivity is observed ( Figure 1B) . OGA-352 and OGA-346 detect a strong signal at~115 kDa, particularly in the MEFs ( Figure 1B) , and the identity of this protein is unknown. OGA-346 also reacts with a strong cross-reacting band just above 150 kDa similar to OGA-A and OGA-B ( Figure 1B) . OGA-345 demonstrates the least cross-reactivity ( Figure 1B) . Overall, all of the antibodies tested recognize fOGA in human and mouse cells, although crossreacting bands warrant appropriate controls, such as deletion of OGA, to confirm specificity.
Enrichment of OGA by immunoprecipitation
We next assessed the utility of OGA-A and OGA-B for enriching fOGA from human and mouse lysates (Figure 2 ). These studies did not use the noncommercially available antibodies, as we have (OGA-B) , or a rabbit isotype control IgG, were used to enrich endogenous OGA from U2OS, MEF OGT WT and MEF OGT null (Δ) lysates (400 μg). Incubation of antibody in buffer was used as a control. The inputs (2.5%), immunoprecipitates (IP; 25%; left panel) and unbound fractions (UB; 2.5%; right panel) were analyzed by SDS-PAGE. WBs were performed for OGA (OGA-345, OGA-A, OGA-B), OGT (positive control) and HSC70 (loading control). This figure is available in black and white in print and in color at Glycobiology online.
previously demonstrated that OGA-345 does not enrich fOGA to saturation and that there is significant background in the chicken IgY isotype control immunoprecipitate (IP) (data not shown). Enriched OGA was detected by WB using OGA-A, OGA-B and OGA-345. Western blotting using OGA-345 reveals a band at 130 kDa in the inputs and IPs (Figure 2 , left panel) representing fOGA (star), which is nearly absent in the unbound fractions (Figure 2, right panel) of the OGA but not IgG IPs. These data suggest that OGA-A (0.5 μg per 100 μg lysate) and OGA-B (0.75 μg per 100 μg lysate) enrich endogenous fOGA to near-saturation from MEFs and U2OS cells. Western blotting using OGA-A and OGA-B demonstrated that these antibodies detect a cross-reacting band at 150 kDa in the MEFs (Figure 2) . Importantly, OGA-A does not enrich this band (Figure 2 ), suggesting that this antibody is suitable for immunoprecipitating fOGA from both human and mouse sources. However, the~150 kDa protein is enriched to saturation by OGA-B in the mouse cell lysates (Figure 2) . Finally, following immunoprecipitation, OGA-A detects a greater amount of overall nonspecific staining compared to OGA-B.
Cross-reacting species detected by OGA-A, OGA-B and OGA-346 near 150 kDa ( Figure 1B ) led us to initially consider the possibility of uncharacterized OGA isoforms. However, the presence of these signals in both the OGT and OGA null lysates does not support this hypothesis. Moreover, if the majority of the antibodies utilized in this study were detecting the same "uncharacterized isoform", we would expect OGA-A to also recognize the~150 kDa protein in the OGA-B MEF IPs. As shown in Figure 2 , this is not the case and supports the notion that the additional signals are simply cross-reacting proteins.
Concluding remarks
The goal of this study was to identify commercial antibodies recognizing OGA that are useful for western blotting and immunoprecipitation. Our studies highlight two commercially available antibodies (Abcam, Bethyl Laboratories) and three noncommercial antibodies (345, 346, 352 ) that recognize fOGA in both human and mouse lysates ( Figure 1B) . However, each antibody recognizes additional bands in the OGT and OGA null MEFs, indicating reactivity with proteins containing similar epitopes. Notably, these cross-reacting proteins often give a stronger signal than fOGA and are close in molecular weight to fOGA ( Figures 1B and 2 ). As such, use of ≤10% gels that provide adequate separation in this molecular weight range are ideal, as are controls in which OGA expression has been suppressed. Both OGA-A and OGA-B IP fOGA from human and mouse lysates to near-saturation, however, enrichment of a~150 kDa protein by OGA-B limits the utility of this antibody in lysates of mouse origin. While not addressed in this study, cross-reacting proteins will likely impede the use of OGA antibodies for immunofluorescence unless antibody specificity is robustly demonstrated. Collectively, our data characterize useful antibodies for immunoprecipitation and western blotting of OGA from mouse and human sources, and highlight technical challenges that can be overcome with appropriate controls.
Materials and methods
Antibodies
The following antibodies were purchased: anti-OGA-A (ab124807; Abcam); anti-OGA-B (A304-345A), anti-chicken IgY-HRP (A30-206P), rabbit isotype control IgG (P120-101; Bethyl Laboratories); anti-OGT (O6264), anti-mouse IgM-HRP (A8786; Sigma-Aldrich); anti-HSC70 (sc-7298; Santa Cruz Biotechnology); and anti-rabbit IgG-HRP (NA934V) and anti-mouse IgG-HRP (NA931V; GE Healthcare). The following previously characterized antigen-purified antibodies were gifts: anti-OGA-345, anti-OGA-346, anti-OGA-352 and anti-O-GlcNAc (CTD110.6) (Comer and Hart 2000; Butkinaree et al. 2008 ).
Cell and tissue preparation and extraction
Cells were cultured in DMEM (Corning) containing 4.5 g/L (U2OS, HEPG2; ATCC) or 1 g/L (OGT WT/null MEFs) glucose, 10% (v/v) heat inactivated FBS (Thermo Fisher Scientific) and 1% (v/v) penicillin/streptomycin (Corning), as previously described (Kazemi et al. 2010; Groves et al. 2017 ). Deletion of OGT was induced with 4-hydroxytamoxifen or vehicle control (100% ethanol) for 40-44 h as previously reported (Kazemi et al. 2010) . OGA WT and null MEF pellets (Keembiyehetty et al. 2015; Olivier-Van Stichelen et al. 2017) were a kind gift from the laboratory of John Hanover, Ph.D. (National Institutes of Health (NIH)).
Mouse care, procedures and liver collections were performed as previously described (Groves et al. 2017) . Cells and livers were lysed in NETN buffer and the protein concentrations were determined as previously reported (Groves et al. 2017 ).
Immunoprecipitation
Endogenous OGA was enriched by incubating cell lysates or buffer with OGA-A, OGA-B or rabbit isotype control IgG (16-20 h, 4°C, with rotation). Antibody-protein complexes were captured using protein G or A/G magnetic beads preblocked with BSA, washed with NETN buffer, and eluted in Laemmli sample buffer containing DTT as previously described (Groves et al. 2017 ).
Electrophoresis and western blotting
These procedures have been reported previously (Groves et al. 2017) . Briefly, SDS-PAGE was performed using 7.5% or 10% TrisGlycine eXtended polyacrylamide gels (Bio-Rad), and then proteins were electroblotted to nitrocellulose. Equal protein loading was assessed prior to blocking using the Sypro Ruby total protein membrane stain according to the manufacturer's instructions. Membranes were blocked in 3% (w/v) nonfat milk in TBS-T (0.05% (v/v) TWEEN-20; 1 h, 25°C), and then incubated with primary (16-20 h, 4°C) and HRP-conjugated secondary (1 h, 25°C) antibodies. WBs were developed using Immobilon Western Chemiluminescent Substrate (EMD Millipore) and captured on autoradiography film or the Amersham Imager 600 RGB (GE Healthcare). Membranes were stripped and re-probed as previously described (Groves et al. 2017) .
Reproducibility
Four biological replicates were independently analyzed for Figure 1B , with the exception of OGA WT and null cells in which one biological replicate was used due to limited sample availability. For Figure 2 , three biological replicates were independently analyzed.
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